about
The human subthalamic nucleus encodes the subjective value of reward and the cost of effort during decision-makingEffectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortResonance in subthalamo-cortical circuits in Parkinson's diseaseUse of intravenous immunoglobulins in clinical practice: data from three French university hospitals.Neuroendocrine disturbances in Huntington's diseaseMethylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.Association between caffeine intake and age at onset in Huntington's disease.Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease.COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence?Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.Postural deformities in Parkinson's disease.Effect of subthalamic deep brain stimulation on non-motor fluctuations in Parkinson's disease.A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias.Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.A motor cortex excitability and gait analysis on Parkinsonian patients.Dopaminergic modulation of the default mode network in Parkinson's disease.Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease.MUSK, a new target for mutations causing congenital myasthenic syndrome.End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.[Movement disorders].A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.[Pathophysiological characterization of congenital myasthenic syndromes: the example of mutations in the MUSK gene].Magnetic stimulation using a triple-stimulation technique in patients with multifocal neuropathy without conduction block.A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation.CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5.Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease.Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia.Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects.Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice.Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?Sensory training with vibration-induced kinesthetic illusions improves proprioceptive integration in patients with Parkinson's disease.Subthalamic nucleus stimulation, dopaminergic treatment and impulsivity in Parkinson's disease.Éditorial.Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.Dopa therapy and action impulsivity: subthreshold error activation and suppression in Parkinson's disease.[No motor signs in Parkinson's disease].
P50
Q27303498-430B434A-4F03-4BDC-AAE8-F571E26E2B68Q28538703-4BFC500E-6F01-4F33-B9ED-F1DBC62A0DFAQ30488968-972C82AA-EC85-407C-BF84-4AC4412BEEEFQ33393579-696B366C-D6E4-4297-94C2-964C18CCD569Q33421708-B92F587A-8439-4DAE-A9E5-57EB9E48E712Q34278569-A6B69E52-39CD-422A-A05F-0BC3B248B289Q34348412-14782E48-AAF8-486D-B3EF-7F638AA577C8Q36132651-25CC5142-862B-4C8E-B8E9-FC5E8D152766Q36140827-AA06A7D7-782E-4E77-84F4-730856425D13Q36502146-CEA40A70-65F3-4FF3-8D8A-36841734A34DQ37631546-67C6D237-3D80-48CD-AE57-A32F5B713A6BQ37868267-C3FCCA5B-EA08-4237-879F-0ADE27F98D27Q38069481-21488341-8547-4270-A12D-6BC4F8036A2DQ38691678-14F7082C-D8FF-4045-B7FB-69DEC8471B29Q39293085-0B3EEC81-3322-44B3-B8B3-A2CE1B031181Q39486694-A4173ACF-36AD-4942-B835-285B2D889183Q41168222-5E59B9B0-5D1D-4799-BC70-F1396C0E95F0Q42868741-4AE75707-777E-4A85-B504-3C8300EB651CQ42950828-D36FFEA5-0745-46CB-9248-9416F1C48101Q43243096-E2FB25C9-2CD3-4322-B406-FDD2FC3A95DCQ45116927-C9707B25-B01B-4269-9F92-CF6451B13EAFQ45279337-EEF0B47C-71CD-491E-847E-24CA9749CC4CQ45298462-4147556C-D5EA-4F47-9EA3-E8D69E2C17C6Q45961748-B6AFA6D8-74E6-452A-8CD4-426D820CF3DBQ46662240-E3C3502A-7D0B-4E84-BEA5-3381B558095FQ46691983-5303425E-4B30-48BF-A1E1-A5C00FD1202EQ47664452-95A3CB30-7FA6-441C-ACCA-6BA11EE96DD2Q47808952-DCE377B2-6237-4CFC-BF61-FA1C26BD4D6AQ47958506-A4500FE5-7002-4ECA-B41F-722011A45F44Q48145567-10725AE0-8785-4E29-85A2-ADE8AFF78D40Q48223759-EBE6C9AF-387F-4EA3-897A-1EACD6D2E52BQ48409969-3ED7BB02-DC38-40BA-B0B0-58526E9D4052Q48433730-3F33B538-C483-42DE-A8FC-B0B8DB3C37EFQ48446114-90B2FDF2-3DBE-4070-882C-00DAA6324DAAQ49794498-8AEB2A4A-7656-4023-B28A-5D50557318DAQ49847971-B7301294-BB6C-40C9-8251-D1830696ECB4Q52888232-216C36B7-4D39-497F-A04F-35A356FB49D7Q53302870-0521C16B-6E9F-47D3-82F3-CB4EAD2C20A9Q53661143-6C946580-7CCA-4700-A3AB-A65DF2748963Q53708057-346E57C3-4CB0-4621-8DC8-22890FFA7B18
P50
name
Jean-Philippe Azulay
@ast
Jean-Philippe Azulay
@en
Jean-Philippe Azulay
@nl
type
label
Jean-Philippe Azulay
@ast
Jean-Philippe Azulay
@en
Jean-Philippe Azulay
@nl
prefLabel
Jean-Philippe Azulay
@ast
Jean-Philippe Azulay
@en
Jean-Philippe Azulay
@nl
P214
P214
P31
P7859
lccn-n99800796